Investing

IPO Week Ahead: GE Spins Out Synchrony in a Whirl of 22 IPOs

Paul Ausick

Tobira Therapeutics Inc. is a clinical stage biopharma developing therapies for liver disease and HIV, among others. The company plans to offer 4.6 million shares in a price range of $12 to $14, raising $60 million. Shares are scheduled to price on Thursday and begin trading Friday on the Nasdaq under the ticker symbol TBRA.

Vascular Biogenics Ltd. is an Israel-based clinical stage biopharma company working on treatments for cancer and other diseases. The company plans to sell 5.4 million shares in a price range of $13 to $15, raising about $76 million. The shares are set to price on Wednesday and begin trading Thursday on the Nasdaq under the ticker symbol VBLX.

Auris Medical Holding AG is a Switzerland-based clinical-stage biopharma company focused on treatment of inner ear disorders. The company plans to sell 6.9 million shares in a price range of $10 to $12 in order to raise about $76 million. The shares are set to price on Thursday and begin trading Friday on the Nasdaq under the ticker symbol EARS.

Bio Blast Pharma Ltd. is an Israel-based development stage biopharma company working on rare and ultra-rare genetic diseases. The company plans to sell 3.3 million shares in a price range of $11 to $13, raising $40 million. The shares are scheduled to price on Thursday and begin trading Friday on the Nasdaq under the ticker symbol ORPN.

FCB Financial Holdings Inc. is a bank holding company that owns a single bank with 54 branches in Florida. The company plans to sell 8.8 million shares in a price range of $24 to $27, raising around $223 million. The shares are expected to price on Thursday and begin trading Friday on the NYSE under the ticker symbol FCB.

Loxo Oncology Inc. is developing cancer treatments for genetically defined patient populations. The company plans to sell 4.4 million shares in a price range of $12 to $14, raising $57 million. The shares are set to price on Thursday and begin trading Friday on the Nasdaq under the ticker symbol LOXO.

Sirva Inc. provides mobility services to multinational corporations and government institutions. The company plans to sell 11.6 million shares in an IPO price range of $15 to $17, raising $186 million. The shares are expected to price on Thursday and begin trading Friday on the Nasdaq under the ticker symbol SRVA.

Delayed from last week was Mapi-Pharma Ltd., a development stage pharmaceutical company that is engaged in developing high barrier to entry and high value-added generic drugs. The Israel-based firm plans to offer 2.3 million shares in an IPO price of $8 to raise $18 million. The shares are expected to price and begin trading this week on the Nasdaq under the ticker symbol MAPI. The per share price was cut from an original range of $13 to $15, and the number of shares was cut back by about 400,000.

Also delayed from last week is Spark Energy Inc., an independent retail natural gas and electricity services provider. The company plans to offer 3 million shares in a price range of $19 to $21, raising a total of $60 million. Shares are set to price on Monday and begin trading Tuesday on the Nasdaq under the ticker symbol SPKE. There were no changes to the terms of this IPO.

One of last week’s scheduled IPOs has been postponed. Atara Biotherapeutics Inc. is a clinical stage biopharma firm that is developing novel therapeutics for muscle wasting conditions and oncology.

ALSO READ: Ten Cities Where Foreign Companies Create the Most Jobs